⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of SK Life Science, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
SK Life Science, Inc.
↗Paramus, United States
SK Life Science, Inc. is a U.S.-based pharmaceutical subsidiary of SK Biopharmaceuticals Co., Ltd., itself part of South Korea’s SK Group. The company is headquartered at 461 From Road, 5th Floor, Paramus, New Jersey, and focuses on commercializing and developing treatments for central nervous system disorders, particularly epilepsy, while expanding into oncology and radiopharmaceutical therapy. The company was founded in the United States in 2002 and changed from SK Energy and Chemical to SK Life Science in 2007. ([sklifescienceinc.com](https://www.sklifescienceinc.com/contact-us/?utm_source=openai))
Its principal commercial product is XCOPRI® (cenobamate), an antiseizure medicine for adults with focal seizures that SK Biopharmaceuticals and SK Life Science developed internally through FDA approval. The broader global pipeline includes carisbamate for Lennox-Gastaut syndrome, cenobamate expansion programs, early CNS assets, oncology programs, targeted protein degradation research through SK Life Science Labs, and the SKL35501/SKL35502 alpha-emitter radiopharmaceutical theranostic program. ([sklifescienceinc.com](https://www.sklifescienceinc.com/innovation/?utm_source=openai))
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:CNS therapeutics, epilepsy, neurology, oncology and radiopharmaceutical therapy
SIZE & FINANCIALS
Employees:201-500
Revenue:$50M-$100M estimated for SK Life Science subsidiary; parent SK Biopharmaceuticals reported 2025 revenue of approximately KRW 706.7B. ([growjo.com](https://growjo.com/company/SK_Life_Science?utm_source=openai))
Founded:2002
Ownership:subsidiary
Status:operating
FUNDING
Investors:SK Biopharmaceuticals Co., Ltd., SK Group
STOCK
Exchange:KOSPI
Ticker:326030 (SK Biopharmaceuticals parent)
Market Cap:$4.09B parent-company market capitalization as of July 2026. ([companiesmarketcap.com](https://companiesmarketcap.com/sk-biopharmaceuticals/marketcap/?utm_source=openai))
PIPELINE
Stage:Commercial; Phase 3; Phase 1; Discovery and Preclinical
Lead Drug Stage:Commercial — XCOPRI® tablets approved and marketed; investigational oral suspension NDA accepted for FDA review with a January 31, 2027 PDUFA target date. ([sklifescienceinc.com](https://www.sklifescienceinc.com/sk-life-science-inc-announces-fda-acceptance-for-review-of-new-drug-application-for-cenobamate-oral-suspension/?utm_source=openai))
Modalities:Small molecule, Oral solid dose, Oral suspension, Radiopharmaceutical therapy, Targeted protein degradation, Molecular glues, AI-enabled digital health
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 3: 1
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Parent Company:SK Biopharmaceuticals Co., Ltd.
Subsidiaries:SK Life Science Labs, King of Prussia, Pennsylvania
Key Partnerships:Angelini Pharma — European development and commercialization of cenobamate/ONTOZRY., Ono Pharmaceutical — Japan development and commercialization rights for cenobamate., Endo International / Endo Ventures — Canadian cenobamate commercialization rights., Ignis Therapeutics — China, Hong Kong and Macao commercialization rights for cenobamate, solriamfetol and other CNS compounds., Eurofarma — Latin American commercialization and 50/50 Mentis Care joint venture for AI-enabled epilepsy care., Dong-A ST — commercialization of cenobamate across approximately 30 countries including Korea., Hikma Pharmaceuticals — exclusive manufacture and commercialization rights for cenobamate in the Middle East and North Africa., Full-Life Technologies — licensing-in relationship supporting the SKL35501/SKL35502 radiopharmaceutical program., LifeSci Venture Partners — open-innovation collaboration., Cala Health — neurology innovation partnership. ([sklifescienceinc.com](https://www.sklifescienceinc.com/about-us/?utm_source=openai))
COMPETITION
Position:Niche Player
Competitors:UCB, Eisai, Jazz Pharmaceuticals, Neurelis, Supernus Pharmaceuticals, Marinus Pharmaceuticals, LivaNova, Catalyst Pharmaceuticals +2 more
LEADERSHIP
Key Executives:
Donghoon Lee - Chief Executive Officer and President
Sunita Misra, MD, PhD - Chief Medical Officer
Lisa Finnerty Lester - Vice President, Commercial Excellence
David F. Cook, PhD - Vice President, Medical Affairs
Kiel Kim - Vice President, Global Business Development
Woojin Choi - Vice President, Head of Business Development, U.S.
Changho Yu - Vice President, Chief Strategy Officer
Darshan Patel, PharmD - Vice President, Global Head of Regulatory Affairs
Chris Lee - Executive Director, Head of CMC and Clinical Supply
LINKS
Website:sklsi.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with SK Life Science, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.